We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
DisperSol Technologies, a clinical-stage pharmaceutical company developing new treatments for oncology and rare diseases, and Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics ...
Reportedly, regulatory action by the USFDA has impacted several new approvals, thus affecting the company's business in various regions including the US that remains the single-largest pharma market globally.